Trial Profile

Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors"

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Levofolinic acid; Oxaliplatin
Indications Colorectal cancer
Focus Biomarker; Pharmacodynamics; Therapeutic Use
Acronyms JACCRO CC-13AR

21 Jul 2020 Status changed from recruiting to active, no longer recruiting.
21 Jul 2020 Planned number of patients changed from 250 to 300.
04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology. Accrual of this trial will continue until the DEEPER trial is completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com